Horizon2020 MMPredict video on personalised medicine tools for myeloma patients now available in five languages

MPE, Myeloma, VideosLeave a comment

Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed to develop a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients. To explain the main goals of MMPredict, MPE filmed a video with some partners working in the project consortium. Now this video, recorded in English, has been translated into four additional languages: German, Spanish, Dutch and Italian.

WECAN workgroup of patient advocates and industry experts releases guiding principles for reasonable legal agreements between patient advocates and pharmaceutical companies

MPELeave a comment

A collaboration between patient advocates and pharmaceutical companies usually requires both parties to sign contracts for different engagements such as for advisory, consultancy, collaborative or speaker engagements. These contracts usually cover areas such as confidentiality, intellectual property, data protection, financial compensation and travel expenses. However, according to the Workgroup of European Cancer Patient Advocacy Networks (WECAN), most of these contracts may be difficult for patient advocates to understand or contain inadequate terms. Aiming to create…

Huge variations between countries in time for reimbursement decisions on new cancer drugs

AccessLeave a comment

European Society for Medical Oncology (ESMO), Munich (Germany) – Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries, according to a study presented at ESMO 2018 Congress.